Abstract
Purpose: To evaluate the impact of radiation therapy (RT) on the longterm outcomes and pattern of failure for T1-2 glottic cancer. Materials and Methods: This is a single-institution, retrospective study. From January (1997 to 2010), 253 patients with early glottic cancer underwent RT by 2-dimensional or 3-dimensional RT with 60Co or linear accelerator. Appropriate daily bolus was applied with linear accelerator-based RT to avoid under dosage of the anterior commissure. Results: A total of 253 patients with T1-T2 glottic cancer were treated with definitive RT. The median age was 65 and males made up 87% of the population. T1 was 77% of the population. The median dose and fraction size were 63 and 2.25 Gy, respectively. After a median followup of 83 months, the locoregional control (LRC) for the whole cohort was 98%. Specifically, LRCs for T1 (195 patients) and T2 (58 patients) were 99.5% and 91%, respectively. Kaplan-Meier curve shows the 5-year cause-specific survival to be 100%. Conclusions: Single-modality RT provides an excellent and effective treatment for T1-T2 glottic cancer with remarkable functional preservation and 5-year LRC of 98% with negligible long-term toxicity.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 580-583 |
| Number of pages | 4 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 36 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 2013 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Early (T1-T2 true vocal cord) glottic cancer
- Radiation therapy
- Squamous cell carcinoma of the larynx
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Long-term follow-up and pattern of failure for T1-T2 glottic cancer after definitive radiation therapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS